Zobrazeno 1 - 10
of 2 385
pro vyhledávání: '"jak inhibitor"'
Autor:
Jennifer Fu, Alexander Egeberg, Susan Holmes, Sergio Vano-Galvan, Martin Steinhoff, Roger Edwards, Gianluca Bonfanti, Ranjit Nagra, Robert Wolk, Helen Tran, Ernest Law
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2759-2769 (2024)
Abstract Introduction Patients with alopecia areata (AA) may have received several therapies for management of AA during their lives. In the ALLEGRO phase 2b/3 (NCT03732807) study, the oral JAK3/TEC family kinase inhibitor ritlecitinib demonstrated e
Externí odkaz:
https://doaj.org/article/534397c42f1f44fc954995f0c43cc375
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1016-1026 (2024)
Abstract Background Chronic hand dermatitis (CHD) has suboptimal treatments and a negative impact on quality of life (QoL). Topical ruxolitinib, a JAK1/JAK2 inhibitor, is approved for vitiligo and mild‐to‐moderate atopic dermatitis, but has not p
Externí odkaz:
https://doaj.org/article/bf1956e37bb142aa8f82841949665c7b
Publikováno v:
Indian Journal of Dermatology, Vol 69, Iss 4, Pp 312-316 (2024)
Background: Chronic spontaneous urticaria (CSU) is a distressing skin condition characterized by the recurrent appearance of itchy hives. A subset of CSU patients remains resistant to conventional treatment with high-dose antihistamines. Tofacitinib,
Externí odkaz:
https://doaj.org/article/b82198e2e39c4bebaebb0de79545d858
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1789-1792 (2024)
Yuzhu Mu, Ting Pan, Lingling Chen Department of Dermatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, 215000, People’s Republic of ChinaCorrespondence: Lingling Chen, Email chenlingli
Externí odkaz:
https://doaj.org/article/d2c4f0cbc49d48e687e381e012e8437a
Autor:
Jacob T. Tribble, BA, Mckinzie Johnson, MD, Yeanna Moon, BA, Anand Rajpara, MD, Jacob Whitsitt, MD
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 119-122 (2024)
Externí odkaz:
https://doaj.org/article/ae29b1f350f140dc9bb026da16ad333e
Autor:
Siddhartha Sood, HBSc, Geeta Yadav, MD
Publikováno v:
JAAD Case Reports, Vol 51, Iss , Pp 38-40 (2024)
Externí odkaz:
https://doaj.org/article/ce2d13f62e3341b08d4109c707a7f6c1
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1298-1300 (2024)
Externí odkaz:
https://doaj.org/article/770611cda130447d98b1053c117a54bb
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 141-143 (2024)
Externí odkaz:
https://doaj.org/article/4e34a5b9e6d049fb99e773630a18d4ce
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 62-64 (2024)
Externí odkaz:
https://doaj.org/article/47f27e59fb0a40c89ca6858e818df0e4
Autor:
Andrea Rubbert-Roth, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, Ricardo M. Xavier
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1197-1215 (2024)
Abstract Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study. Methods Patients with RA refr
Externí odkaz:
https://doaj.org/article/d313932347fc4677b9fb4fe93f411d0d